Details of Disease

General Information of Disease (ID: DIS1OJKM)

Disease Name Blood forming organ disorder
Disease Class JB63: Pregnancy/childbirth/puerperium maternal infection
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DIS1OJKM: Blood forming organ disorder
ICD Code
ICD-11
ICD-11: JB64.1
ICD-10
ICD-10: O99.1

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AMT-011 DM8QIRN Phase 3 NA [1]
Ancrod DMK2Y4V Phase 3 NA [2]
PolyHeme DMV8EXG Phase 3 NA [3]
Recombinant batroxobin DMURX4B Phase 2 NA [4]
TTP889 DMCQARM Phase 2 Small molecular drug [5]
Human Factor XIII DMF1T4B Phase 1 NA [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 1 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ARC-183 DMKLCRI Discontinued in Phase 1 Aptamer [7]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
APT3111 DMGT1HI Investigative NA [8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
2 ClinicalTrials.gov (NCT00141011) Ancrod (Viprinex for the Treatment of Acute, Ischemic Stroke. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00076648) Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting. U.S. National Institutes of Health.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028815)
5 Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
6 ZymoGenetics Licenses Recombinant Factor XIII to Novo Nordisk. ZymoGenetics, Inc. Oct. 5, 2004.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019755)
8 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.